[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Equilyse [@equilyse1](/creator/twitter/equilyse1) on x XXX followers Created: 2025-07-24 11:39:38 UTC $TMO: Thermo Fisher Scientific $TMO reported solid Q2 2025 earnings, beating guidance with revenue up X% to $10.85B and adjusted EPS at $XXXX. They're raising full-year guidance to $43.6-44.2B in revenue and $22.22-22.84 adjusted EPS, driven by their growth strategy and PPI Business System. Tariffs and FX headwinds impacted adjusted operating income by 5%—140 basis points on margins—but strong earnings growth elsewhere offset this. Innovation remains key, with new products like the Orbitrap Astral Zoom mass spectrometer gaining positive customer feedback. Strategic capital deployment continues with the Solventum acquisition on track—excluding the drinking water filtration business—and expansion of U.S. manufacturing via Sanofi site acquisition. Pharma/biotech saw mid-single-digit growth, while academic/government declined amid customer hesitancy. $TMO anticipates 3-6% organic revenue growth in 2026-2027.  XX engagements  **Related Topics** [tariffs](/topic/tariffs) [$436442b](/topic/$436442b) [eps](/topic/eps) [$1085b](/topic/$1085b) [$tmo](/topic/$tmo) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/equilyse1/status/1948347339262808491)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Equilyse @equilyse1 on x XXX followers
Created: 2025-07-24 11:39:38 UTC
$TMO: Thermo Fisher Scientific $TMO reported solid Q2 2025 earnings, beating guidance with revenue up X% to $10.85B and adjusted EPS at $XXXX. They're raising full-year guidance to $43.6-44.2B in revenue and $22.22-22.84 adjusted EPS, driven by their growth strategy and PPI Business System.
Tariffs and FX headwinds impacted adjusted operating income by 5%—140 basis points on margins—but strong earnings growth elsewhere offset this. Innovation remains key, with new products like the Orbitrap Astral Zoom mass spectrometer gaining positive customer feedback.
Strategic capital deployment continues with the Solventum acquisition on track—excluding the drinking water filtration business—and expansion of U.S. manufacturing via Sanofi site acquisition. Pharma/biotech saw mid-single-digit growth, while academic/government declined amid customer hesitancy. $TMO anticipates 3-6% organic revenue growth in 2026-2027.
XX engagements
Related Topics tariffs $436442b eps $1085b $tmo stocks healthcare